ABCL - AbCellera Biologics Inc.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago.
AbCellera Biologics NASDAQ: ABCL said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration DUBLIN and VANCOUVER, BC, June 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.
DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies.
AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions.